Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1678 • ACR Convergence 2021
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Maarten Boers¹, Linda Hartman¹, Daniela Opris-Belinski², Reinhard Bos³, Marc Kok⁴, Jose Pereira da Silva⁵, Ed Griep⁶, Ruth Klaasen⁷, Cornelia F. Allaart⁸, Paul Baudoin⁹, Hennie Raterman¹⁰, Zoltan Szekanecz¹¹, Frank Buttgereit¹², Pavol Masaryk¹³, L. Thomas Klausch¹, Sabrina Paolino¹⁴, Annemarie Schilder³, Willem Lems¹⁵ and Maurizio Cutolo¹⁴, ¹Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ²Carol Davila University, Bucharest, Romania, ³Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Maasstad Hospital, Rotterdam, Netherlands, ⁵University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, ⁶Antonius Hospital, Sneek, Netherlands, ⁷Meander Medical Center, Amersfoort, Netherlands, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Reumazorg Flevoland, Emmeloord, Netherlands, ¹⁰Northwest Clinics, Alkmaar, Netherlands, ¹¹Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, ¹²Charité – Universitätsmedizin Berlin, Berlin, Germany, ¹³National Institute for the Rheumatic Diseases, Bratislava, Slovakia, ¹⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ¹⁵VUmc, Amsterdam, Netherlands
Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
Abstract Number: 1694 • ACR Convergence 2021
Sustainability of Response to Upadacitinib Among Patients with Active Rheumatoid Arthritis Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs
Ronald van Vollenhoven¹, Stephen Hall², Alvin Wells³, Sebastian Meerwein⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³Rheumatology and Immunotherapy Center, Franklin, WI, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being an appropriate target…
Abstract Number: 1712 • ACR Convergence 2021
Adverse Outcomes and Rehospitalization After Delivery Among Women with Systemic Lupus Erythematosus or Rheumatoid Arthritis and Their Infants
Julianna Sabo¹, Namrata Singh², Deborah Crane¹, David Doody³, Melissa Schiff⁴ and Beth Mueller⁵, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³Fred Hutchinson Cancer Research Center, Seattle, WA, ⁴University of Washington, University of New Mexico, Seattle, WA, ⁵Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Women with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) have greater risk of adverse obstetric and birth outcomes than women without these conditions.…
Abstract Number: 1938 • ACR Convergence 2021
A Phenome-Wide Association Study of Genes Associated with COVID-19 Severity Reveals Shared Genetics with Rheumatic Conditions
Anurag Verma¹, Noah Tsao¹, Lauren Thomann², Yuk-Lam Ho², Rotonya Carr¹, Dana crawford³, Jimmy efird⁴, Jennifer Huffman², Adriana Hung⁵, Kerry Ivey², Sudha Iyengar³, Michael Levin⁶, Shiuh-Wen luoh⁷, Julie Lynch⁸, Pradeep Natarajan⁹, Saiju Pyarajan¹⁰, alexander Bick¹¹, Lauren Costa², Giulio Genovese¹², Richard Hauger¹³, Ravi madduri¹⁴, Gita Pathak¹⁵, Renato polimanti¹⁵, Benjamin Voight¹, Marijana Vujkovic¹, Maryam Zekavat¹⁵, Hongyu Zhao¹⁵, Marylyn Ritchie¹, Kyong-Mi Chang¹⁶, Kelly Cho², Juan casas², Phil Tsao¹⁷, J. Michael Gaziano², Christopher ODonnell², Scott Damrauer¹ and Katherine Liao¹⁸, ¹University of Pennsylvania, Philadelphia, PA, ²VA Boston Healthcare System, Boston, MA, ³Case Western Reserve University, Cleveland, OH, ⁴DVAHCS, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Pennsylvania, Philadelphia, ⁷Oregon Health & Science University, Portland, ⁸VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Partners, Boston, ¹¹Vanderbilt University, Nashville, TN, ¹²Harvard Medical School, Boston, MA, ¹³University of California San Diego, San Diego, CA, ¹⁴Argon National Lab, Chicago, IL, ¹⁵Yale University, New Haven, CT, ¹⁶VA Philadelphia, Philadelphia, PA, ¹⁷VA Palo Alto, Palo Alto, CA, ¹⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Severe coronavirus disease 2019 (COVID-19) is associated with a broad range of clinical conditions. International efforts have led to the identification of risk alleles…
Abstract Number: 0024 • ACR Convergence 2021
Heterogeneity of Inflammatory HLA-DR+ Synovial Fibroblasts in Rheumatoid Arthritis Is Driven by Responses to Leukocyte-Derived Cytokines
Melanie Smith¹, Alejandro Kochen¹, Vianne Gao², Michail Schizas², Edward DiCarlo¹, Susan Goodman¹, Christina Leslie³, Laura Donlin¹ and Alexander Rudensky⁴, ¹Hospital for Special Surgery, New York, NY, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Computational and Systems Biology Program Memorial Sloan Kettering Cancer Center, New York, NY, ⁴Memorial Sloan Kettering Cancer Center / Howard Hughes Medical Institute, New York, NY
Background/Purpose: Treatment-refractory rheumatoid arthritis (RA) represents a major unmet need with substantial societal burden. Targeting RA-associated fibroblast-like synoviocytes (FLS) may provide a less-immunosuppressive therapeutic option.…
Abstract Number: 0040 • ACR Convergence 2021
M1-M2 Polarization by CTLA4-Ig (Abatacept) on Cultured Circulating Monocytes from Rheumatoid Arthritis Patients and Healthy Subjects
Samuele tardito¹, Stefano Soldano², Emanuele Gotelli², Paola Montagna¹, Rosanna Campitiello², Sabrina Paolino², Carmen Pizzorni¹, Alberto Sulli², Vanessa Smith³ and Maurizio Cutolo², ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Dept. Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, ³Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disorder affecting 1% of the population worldwide [1]. Monocytes/macrophages are known to play a crucial role in…
Abstract Number: 0137 • ACR Convergence 2021
Antiviral Use and Healthcare Resource Utilization Among Patients with Rheumatoid Arthritis and Influenza in Three Influenza Seasons, 2016–2019
Edward Neuberger¹, Tu My To¹, Arpamas Seetasith¹, Stella Arndorfer² and Christopher Wallick¹, ¹Genentech, Inc., South San Francisco, CA, ²Genesis Research, South San Francisco, CA
Background/Purpose: Seasonal influenza poses a large burden on the healthcare system. Patients with certain chronic diseases, such as rheumatoid arthritis (RA), are especially vulnerable to…
Abstract Number: 0227 • ACR Convergence 2021
Work Participation Is Impaired Months Before Clinical Arthritis Is Apparent
Cleo Rogier¹, Pascal de Jong², Annette H.M van der Helm-van Mil³ and Elise van Mulligen⁴, ¹Erasmus MC, Rotterdam, ²Erasmus MC, Hendrik Ido Ambacht, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Work participation is still a major issue for patients with rheumatoid arthritis (RA) despite improved management and outcomes. Work loss can be divided into…
Abstract Number: 0281 • ACR Convergence 2021
Unsupervised Machine Learning of Expanded Autoantibodies, Cytokines, and Chemokines Improves the Identification of Interstitial Lung Disease in Rheumatoid Arthritis
Bryant England¹, Dana Ascherman², Michael Duryee¹, Carlos Hunter¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Fang Yu¹, Jill Poole¹, Joshua Baker³, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Interstitial lung disease (ILD) frequently complicates the rheumatoid arthritis (RA) disease course, leading to significant morbidity and premature mortality. RA-ILD may be underdiagnosed or…
Abstract Number: 0428 • ACR Convergence 2021
ANCA Positivity and ANCA Associated Vasculitis in Patients with Rheumatoid Arthritis
Courtney O'Brien, Veena Ranganath and Tannaz Kermani, University of California Los Angeles, Los Angeles, CA
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) with rheumatoid arthritis (RA) has been reported rarely, and, studies have found ANCA positivity in RA. The…
Abstract Number: 0529 • ACR Convergence 2021
COPA Syndrome-associated Mutations in Lung Transplant Recipients for Interstitial Lung Disease
Sarah Beshay¹, Isabella Osuna², Jessica Smith¹, Justin Branch³, Laura Muruato³, Marietta DeGuzman³, Pamela McShane¹, Yuelan Ren¹, Rajeev Singh¹, Manuel Silva Carmona³, Sandeep Sahay¹ and Tiphanie Vogel³, ¹Houston Methodist, Houston, ²Rice University, Houston, TX, ³Baylor College of Medicine, Houston, TX
Background/Purpose: COPA syndrome is a rare monogenic cause of immune-mediated lung disease, and it can mimic rheumatic diseases including rheumatoid arthritis (RA) with ILD, lupus…
Abstract Number: 0583 • ACR Convergence 2021
Obesity and Lower Socioeconomic Position Are Independently Associated with Incident Osteoarthritis and Rheumatoid Arthritis: Results from the English Longitudinal Study of Ageing
Rozemarijn Witkam¹, James Gwinnutt¹, Jennifer Humphreys¹, Rachel Cooper², David Selby¹ and Suzanne Verstappen³, ¹University of Manchester, Manchester, United Kingdom, ²Manchester Metropolitan University, Manchester, United Kingdom, ³School of Social Sciences, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Obesity is a known risk factor for OA and hypothesised as a risk factor for RA, although due to different underlying mechanisms. Lower socioeconomic…
Abstract Number: 0613 • ACR Convergence 2021
Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
J. Thomas Berry, William Galanter, Alia Welsh, Sandra Folarin, Reginald Woods and Huan Chang, UIC Medical Center, Chicago, IL
Background/Purpose: African Americans and Hispanics with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) continue to have worse disease-related health outcomes relative to Whites. This…
Abstract Number: 0789 • ACR Convergence 2021
Adipokine Levels and Associations with Achievement of Low Disease Activity in Rheumatoid Arthritis
Joshua Baker¹, Bryant England², Michael George¹, Katherine Wysham³, Gail Kerr⁴, Andreas Reimold⁵, Paul Monach⁶, Gary Kunkel⁷, Brian Sauer⁷, Bartlett Hamilton⁸, Carlos Hunter², Michael Duryee², Geoffrey Thiele² and Ted Mikuls², ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁶Brigham and Women's Hospital, Boston, MA, ⁷University of Utah, Salt Lake City, UT, ⁸University of Nebraska, Omaha, NE
Background/Purpose: Adipokines are fat-secreted proteins that serve as metabolic regulators. Prior studies have identified associations between adipokines and disease characteristics such as disease activity and…
Abstract Number: 0805 • ACR Convergence 2021
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
Panagiotis Athanassiou¹, Dimitrios Psaltis², Athanasios Georgiadis³, Gkikas Katsifis⁴, Athina Theodoridou⁵, Souzana Gazi⁶, Prodromos Sidiropoulos⁷, Maria Tektonidou⁸, Andreas Bounas⁹, Anna Kandyli¹⁰, Periklis Vounotrypidis⁵, Grigorios Sakellariou⁵, Dimitrios Vassilopoulos¹¹, Zhiping Huang¹², Evangelia Petrikkou¹³ and Dimitrios Boumpas¹⁴, ¹Department of Rheumatology, St. Paul’s Hospital of Thessaloniki, Thessaloniki, Greece, ²Private Practice, Serres, Greece, Athens, Greece, ³Private Practice, Ioannina, Greece, Athens, Greece, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Private Practice, Thessaloniki, Greece, Athens, Greece, ⁶“KAT” Regional General Hospital, Rheumatology Unit, Athens, Greece, Athens, Greece, ⁷Department of Rheumatology, Clinical Immunology and Allergy, University of Crete, Heraklion, Greece, ⁸Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Joint Rheumatology Program, Laiko Hospital, Athens, Greece, ⁹General Clinic of Patras “Olympion”, Rheumatology, Patras, Greece, ¹⁰Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ¹¹2nd University Department of Internal Medicine, General Hospital of Athens "Ippokrateion", Athens, Greece, ¹²Merck & Co., Inc., Pharmacoepidemiology, Center for Observational and Real-world Evidence (CORE), Kenilworth, NJ, ¹³MSD Pharmaceutical, Industrial and Commercial S.A, Athens, Medical Affairs, Athens, Greece, ¹⁴Rheumatology and Clinical Immunology, 4th Department of Internal Medicine, ‘‘Attikon’’ University Hospital, Athens, Greece
Background/Purpose: Patients (pts) with immune-mediated rheumatic diseases and an insufficient response to previous treatment with TNFα inhibitors (TNFαi) are frequently encountered in clinical practice. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].